Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Bando

Showing results (61-70 of 186) with videos related to

Pageof 19
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 23, 2016
A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201)Hideaki Bando, Toshihiko Doi, Kei Muro, et al.
Japanese Journal of Clinical Oncology|October 17, 2012
Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecanHideaki Bando, Takayuki Yoshino, Satoshi Yuki, et al.
Japanese Journal of Clinical Oncology|January 17, 2024
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studiesShunji Takahashi, Hideaki Bando, Ichiro Kinoshita, et al.
Esophagus : Official Journal of the Japan Esophageal Society|January 23, 2020
Therapeutic results of proton beam therapy with concurrent chemotherapy for cT1 esophageal cancer and salvage endoscopic therapy for local recurrenceDaiki Sato, Atsushi Motegi, Tomohiro Kadota, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2018
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancerHideaki Bando, Hideki Shimodaira, Kazumasa Fujitani, et al.
Cancer Science|August 8, 2019
Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trialYasuhiro Shimizu, Toshiaki Yoshikawa, Takashi Kojima, et al.
Journal of Gastrointestinal Cancer|September 22, 2025
Survival Outcomes of Patients with BRAF V600E-Mutant Resectable Extrahepatic Colorectal Oligometastases After Upfront MetastasectomyTakashi Mori, Shin Kobayashi, Yuichiro Tsukada, et al.
International Journal of Clinical Oncology|June 6, 2026
Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational StudyKyosuke Seguchi, Tadayoshi Hashimoto, Takao Fujisawa, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 11, 2019
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancerAkinori Sasaki, Yoshiaki Nakamura, Saori Mishima, et al.
Clinical Colorectal Cancer|April 28, 2024
Appropriate Relevancy and Reliability of Real-World Data for the Utilization of Regulatory SubmissionHideaki Bando, Toshihiro Misumi, Yasutoshi Sakamoto, et al.
Pageof 19

Showing results (61-70 of 186) with videos related to

Sort By:
Pageof 19
European Journal of Cancer (Oxford, England : 1990)|May 23, 2016
A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201)Hideaki Bando, Toshihiko Doi, Kei Muro, et al.
Japanese Journal of Clinical Oncology|October 17, 2012
Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecanHideaki Bando, Takayuki Yoshino, Satoshi Yuki, et al.
Japanese Journal of Clinical Oncology|January 17, 2024
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studiesShunji Takahashi, Hideaki Bando, Ichiro Kinoshita, et al.
Esophagus : Official Journal of the Japan Esophageal Society|January 23, 2020
Therapeutic results of proton beam therapy with concurrent chemotherapy for cT1 esophageal cancer and salvage endoscopic therapy for local recurrenceDaiki Sato, Atsushi Motegi, Tomohiro Kadota, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2018
A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancerHideaki Bando, Hideki Shimodaira, Kazumasa Fujitani, et al.
Cancer Science|August 8, 2019
Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trialYasuhiro Shimizu, Toshiaki Yoshikawa, Takashi Kojima, et al.
Journal of Gastrointestinal Cancer|September 22, 2025
Survival Outcomes of Patients with BRAF V600E-Mutant Resectable Extrahepatic Colorectal Oligometastases After Upfront MetastasectomyTakashi Mori, Shin Kobayashi, Yuichiro Tsukada, et al.
International Journal of Clinical Oncology|June 6, 2026
Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational StudyKyosuke Seguchi, Tadayoshi Hashimoto, Takao Fujisawa, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 11, 2019
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancerAkinori Sasaki, Yoshiaki Nakamura, Saori Mishima, et al.
Clinical Colorectal Cancer|April 28, 2024
Appropriate Relevancy and Reliability of Real-World Data for the Utilization of Regulatory SubmissionHideaki Bando, Toshihiro Misumi, Yasutoshi Sakamoto, et al.
Pageof 19